Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

ABSTRACT:

Background

Genetic mutations drive the pathogenesis of the myelodysplastic syndrome (MDS) and are closely associated with clinical phenotype. Therefore, genetic mutations may predict clinical outcomes after allogeneic hematopoietic stem-cell transplantation.

Methods

We performed targeted mutational analysis on samples obtained before transplantation from 1514 patients with MDS who were enrolled in the Center for International Blood and Marrow Transplant Research Repository between 2005 and 2014. We evaluated the association of mutations with transplantation outcomes, including overall survival, relapse, and death without relapse.

Results

TP53 mutations were present in 19% of the patients and were associated with shorter survival and a shorter time to relapse than was

SUBMITTER: Lindsley RC 

PROVIDER: S-EPMC5438571 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature